Drug Eluting Balloon Market Size 2021 Emerging Trends, Industry Share, Opportunities, Regional Overview and SWOT Analysis till 2027
A drug eluting balloon, also known as drug-coated balloon, is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon. Drug eluting balloons have also been investigated in clinical trials to prevent coronary artery in-stent restenosis. These balloons homogenously deliver medication to the vessel and prevents neointimal hyperplasia.
Request Sample is Available @ https://www.coherentmarketinsights.com/insight/request-sample/2459
Market players are focusing on launching novel drug eluting balloons to address the critical unmet needs of patients and treat coronary artery disease and other diseases, driving the growth of the global drug eluting balloon market. For example, in July 2016, Medtronic received FDA approval for the IN.PACT Admiral drug-coated balloon (DCB) to provide greater treatment options for long lesions in patients with peripheral artery disease (PAD).
Moreover, in 2014, the Food and Drug Administration (FDA) approved C.R. Bard’s Lutonix 035 Drug Coated Balloon (Lutonix DCB), a technology that may reduce restenosis of vessels treated by balloon angioplasty. This technology is approved for use in the femoral and popliteal arteries when they are stricken by Peripheral Artery Disease (PAD).
Launch of novel drug eluting balloons by market players to augment the market growth Key players in the market are focused on launching novel drug eluting balloons in order to treat coronary artery disease and other diseases and address the critical unmet needs of patients. For instance, in October 2014, C.R. Bard’s received U.S. Food and Drug Administration (FDA) approval for Lutonix 035 drug eluting balloon that is used in popliteal arteries in upper legs.
Similarly, in January 2015, Medtronic received clearance from the U.S. FDA for In.Pact Admiral Drug eluting balloon that is used in the superficial femoral and popliteal arteries in upper legs, thereby providing new opportunities for Medtronic and C.R. Bard’s in offering effective treatment options among the fastest growing markets worldwide. In July 2017, Spectranetics Corp. received pre-market approval (PMA) from U.S. FDA for Stellarex drug coated balloon that is used for restoration and maintenance of blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease.
Request Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/2459
By Product Type:
- Coronary Drug Eluting Balloon
- Peripheral Drug Eluting Balloon
By End User:
- CATH Laboratories
- Ambulatory Surgical Centers
Major players operating in the global drug eluting balloon market are Medtronic, Biotronik, Surmodics, Terumo Corporation, Opto Circuits Limited, Koninklijke Philips N.V., B. Braun Melsungen AG, Cook Medical, Boston Scientific Corporation, and Becton, Dickinson and Company (BD).
In November 2016, the Spectranetics Corporation announced that it has submitted its Pre-Market Approval (PMA) application to FDA for the Stellarex drug-coated angioplasty balloon (DCB); designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease (PAD).
Buy This Complete A Business Report With Flat US $2000 Off @
Table of Content
Global Drug Eluting Balloon Market Research Report
Section 1: Global Drug Eluting Balloon Industry Overview
Section 2: Global Economic Impact on Drug Eluting Balloon Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Drug Eluting Balloon Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire